MDM4 haploinsufficiency leads to p53-mediated bone marrow failure

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Bone marrow failure (BMF) syndromes are diverse genetic disorders impacting blood cell production.
• These syndromes carry a risk of progressing to myelodysplastic syndrome (MDS) and leukemia.
• The genetic underpinnings of many BMF syndromes remain incompletely understood.

Purpose of the Study:

• To investigate the role of MDM4 gene variants in patients presenting with BMF and MDS.
• To elucidate the molecular mechanisms by which MDM4 alterations affect hematopoiesis.
• To establish MDM4 deficiency as a novel genetic cause of BMF syndromes.

Main Methods:

• Genomic analysis of unrelated individuals with BMF and hypocellular MDS.
• CRISPR/Cas9 gene editing to create MDM4-haploinsufficient hematopoietic stem and progenitor cells (HSPCs).
• Utilizing induced pluripotent stem cells (iPSCs) to model patient-specific MDM4 variants and assess their impact on hematopoiesis.
• RNA sequencing and transcriptome analysis to examine gene expression changes.

Main Results:

• Identified germline heterozygous variants in MDM4 in six unrelated individuals with BMF and MDS.
• Demonstrated that MDM4 loss-of-function leads to enhanced p53 activation, impairing HSPC function and engraftment.
• Confirmed that MDM4 variants in iPSCs result in reduced erythroid and myeloid cell production and increased p53 activity.
• Observed acquired TP53 mutations in one patient with MDS, suggesting a potential maladaptive rescue mechanism.

Conclusions:

• MDM4 deficiency is a novel TP53-activating syndrome associated with BMF and variable hematopoietic abnormalities.
• The MDM4-p53 axis plays a critical role in maintaining hematopoietic homeostasis.
• This study expands the genetic landscape of BMF syndromes and provides mechanistic insights into p53 pathway dysregulation in hematopoiesis.